Sectors
Foley & Lardner LLP partner Aaron Maguregui and senior counsel Matthew Horton are featured for their insights on the value of patents for digital health platforms in the HealthExec article, “AI roundup: Of workslop and rework | Patent that tech, industry player | Artificial Intellectualism, anyone?”
In their recent Foley Health Care Law Today article cited by HealthExec, Maguregui and Horton explain why digital health companies must treat patents as a core strategic tool.
“In today’s AI-enabled healthcare market, patents are not optional legal artifacts,” the authors write. “They are a strategic business tool that protects enterprise valuation, strengthens defensibility, shapes competitive leverage, and reduces downside exposure.”
HealthExec highlighted several of their key points, including how many digital health companies delay patenting at their own risk, well‑designed digital health patents protect the core system‑level AI functionality that drives competitive advantage, strong patent portfolios signal technical credibility and stability to enterprise buyers, and patents help distinguish meaningfully differentiated AI platforms from those at risk of commoditization.
“For companies building the next generation of health care platforms, the question is simple. If the technology is worth building, it is worth protecting,” the authors conclude.
